#13: TheMachine: AMEN Stock News : Amarin Announces Results from Exploratory Phase 2a Study of EN101 in Myasthenia Gravis
Amends Ester Neurosciences Acquisition Agreement
Amarin Corporation... |
June 10, 2009
08:03:22 AM |
#12: TheMachine: Amarin Regains Compliance With Nasdaq Listing Requirements
LONDON, February 11 /PRNewswire-FirstCall/ --... |
February 16, 2008
02:44:38 AM |
#11: TheMachine: Amarin Appoints Dr. William Mason as Lead Independent Director
LONDON, February 4 /PRNewswire-FirstCall/ --... |
February 16, 2008
02:44:15 AM |
#10: TheMachine: Dutton Associates Announces Investment Opinion: Amarin Rating Raised To Speculative Buy By Dutton Associates
Dutton Associates continues coverage of Amarin Corporation plc... |
February 16, 2008
02:43:55 AM |
#9: Stock News Bot: Amarin Signs Agreement to Acquire Ester Neurosciences
Adds Promising Phase II Neurology Candidate
$8.1 Million Financing in Connection... |
December 12, 2007
05:56:52 AM |
#8: FastFun: Amarin Commences First Clinical Trial in Cardiovascular ProgramAmarin Commences First Clinical Trial in Cardiovascular Program
Initiates Phase I Clinical Trial to Evaluate Ultra-Pure Ethyl EPA-Niacin... |
December 1, 2007
06:13:05 PM |
#7: FastFun: Amarin Announces Completion of Comprehensive Data Analysis From
LONDON, November 19 /PRNewswire-FirstCall/ -- Amarin Corporation plc... |
December 1, 2007
06:10:49 PM |
#6: FastFun: Amarin Announces Initiation of Cardiovascular Development Strategy
Capitalizing on Known Therapeutic Benefits of Unsaturated Fatty Acids in... |
October 17, 2007
10:31:13 PM |
#5: FastFun: Amarin to Present at 4th Annual Bio Investor Forum
LONDON, October 9 /PRNewswire-FirstCall/ -- Amarin Corporation plc... |
October 17, 2007
10:30:37 PM |
#4: FastFun: Amarin Announces Publication of Pre-Clinical Memory Data in Journal of Neurochemistry
Pre-Clinical Study Results for Memory and Cognition Validate Clinical... |
October 17, 2007
10:30:03 PM |
#3: Stock News Bot: AMRN News Dutton Associates Announces Investment Opinion: Amarin Rating Maintained At Strong Speculative Buy By Dutton Associates
EL DORADO HILLS, Calif.--(BUSINESS WIRE)--Dutton Associates continues coverage of... |
February 28, 2007
09:00:00 AM |
#2: Stock News Bot: AMRN News Dutton Associates Announces Investment Opinion: Amarin Rating Raised To Strong Speculative Buy By Dutton Associates
EL DORADO HILLS, Calif.--(BUSINESS WIRE)--July 25, 2006--Dutton Associates... |
July 25, 2006
09:00:00 AM |
#1: Stock News Bot: AMRN News MultiCell Technologies In-Licenses Phase IIb/III Drug for the Treatment of Fatigue in Multiple Sclerosis from Amarin Corporation
LINCOLN, R.I. & LONDON--(BUSINESS WIRE)--Jan. 3, 2006--MultiCell Technologies,... |
January 3, 2006
03:00:00 AM |
